Skip to content
Sample Page
Author:
Atea Pharmaceuticals, Inc.
Posted Date:
July 14, 2026
Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus
Atea Pharmaceuticals, Inc.
July 14, 2026
Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
Atea Pharmaceuticals, Inc.
June 25, 2026
